9 Pages
English

EXJADE - EXJADE - CT 3381 - English version

Gain access to the library to view online
Learn more

Description

Introduction EXJADE 125 mg, dispersible tablets Box of 28 (CIP 376 951-1); box of 84 (CIP 376 952-8) EXJADE 250 mg, dispersible tablets Box of 28 (CIP 376,953-4); box of 84 (CIP 376,9540) EXJADE 500 mg, dispersible tablets Box of 28 (CIP 376,955-7); box of 84 (CIP 376,956-3) Posted on Aug 01 2008 Active substance (DCI) deferasirox ATC Code V03AC03 Laboratory / Manufacturer NOVARTIS PHARMA S.A.S. EXJADE 125 mg, dispersible tablets Box of 28 (CIP 376 951-1); box of 84 (CIP 376 952-8) EXJADE 250 mg, dispersible tablets Box of 28 (CIP 376,953-4); box of 84 (CIP 376,9540) EXJADE 500 mg, dispersible tablets Box of 28 (CIP 376,955-7); box of 84 (CIP 376,956-3) Posted on Aug 01 2008

Subjects

Informations

Published by
Published 20 September 2006
Reads 12
Language English
  
  
 The legally binding text is the original French version  TRANSPARENCY COMMITTEE
Opinion
 20 September 2006   EXJADE 125 mg, dispersible tablets Box of 28 (CIP 376 951-1); box of 84 (CIP 376 952-8)  EXJADE 250 mg, dispersible tablets Box of 28 (CIP 376,953-4); box of 84 (CIP 376,9540)  EXJADE 500 mg, dispersible tablets Box of 28 (CIP 376,955-7); box of 84 (CIP 376,956-3)  Applicant : NOVARTIS PHARMA S.A.S.  deferasirox  List I Medicinal product for hospital prescription only Medicinal product requiring special monitoring during treatment  Date of Marketing Authorisation: 28.08.06  Reason for request: Inclusion on the list of medicines reimbursed by French National Insurance and approved for use by hospitals                    Health Technology Assessment Division 1  
)